Key statistics
As of last trade, Immuneering Corp (IMRX:NMQ) traded at 3.06, 206.00% above the 52 week low of 1.00 set on Aug 16, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.15 |
---|---|
High | 3.35 |
Low | 3.01 |
Bid | 3.05 |
Offer | 3.06 |
Previous close | 3.21 |
Average volume | 40.78m |
---|---|
Shares outstanding | 29.65m |
Free float | 21.00m |
P/E (TTM) | -- |
Market cap | 95.19m USD |
EPS (TTM) | -1.91 USD |
Data delayed at least 15 minutes, as of Sep 23 2024 15:12 BST.
More ▼
- Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients
- Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
- Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates
- Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer
- Immuneering to Present at the Jefferies Global Healthcare Conference
- Immuneering Recognizes Melanoma Awareness Month
- IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models
- Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference
- Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
- Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors
More ▼